Manjool Shah, MD
Ophthalmology · Ann Arbor, MINPI 1447576186
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by AbbVie at 55.2% of the total. Among ophthalmology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 584 payments — averaging $1042.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$336K
- Alcon$114K
- Glaukos Corporation$86K
- NEW World Medical,inc.$16K
- Surgical Specialties Corporation (US), Inc. (dba Corza Medical)$14K
- Nova Eye, Inc.$10K
- plus $33K from 12 others
Across 63 payments — averaging $2177.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$126K
- Ivantis, Inc$12K
What the payments were for
- Consulting fees$301,26949%
- Speaking & faculty fees$250,31041%
- Travel & lodging$43,5997%
- Food & beverage$13,6192%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 407 | $335,764 |
| Alcon | 59 | $113,757 |
| Glaukos Corporation | 46 | $85,836 |
| NEW World Medical,inc. | 24 | $16,212 |
| Surgical Specialties Corporation (US), Inc. (dba Corza Medical) | 1 | $14,332 |
| Nova Eye, Inc. | 5 | $10,309 |
| Bausch & Lomb Americas Inc. | 11 | $9,063 |
| Ivantis, Inc | 4 | $5,715 |
| Sight Sciences, Inc. | 7 | $4,330 |
| Microsurgical Technology, Inc. | 2 | $4,000 |
| Beaver-visitec International, Inc. | 3 | $3,869 |
| Ocular Therapeutix, Inc. | 3 | $2,089 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $1,949 |
| Aerie Pharmaceuticals, Inc. | 1 | $600 |
| Alcon Research LLC | 1 | $500 |
| Carl Zeiss Meditec, Inc. | 2 | $392 |
| Thea Pharma Inc. | 2 | $64 |
| Biotissue Holdings Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEN GLAUCOMA TREATMENT SYSTEM$128,134
- Hydrus Microstent$114,192
- DURYSTA$107,272
- XEN$60,752
- iDose$22,914
- Ahmed Glaucoma Valve$15,099
- Kahook Dual Blade$15,099
- iStent inject Trabecular Micro-Bypass System Model G2-M-IS$10,894
- Clearpath$8,617
- Streamline$8,617
- VYZULTA$8,452
- Via360$7,260
- iStent inject Trabecular Micro-Bypass Stent System$5,000
- iStent Trabecular Micro-Bypass Stent System$4,875
- OMNI(R) SURGICAL SYSTEM (US)$4,276
- SION SURGICAL INSTRUMENT$4,127
- Travoprost Intraocular Implant - iDose$3,713
- LUMIGAN$3,433
- iStent Trabecular Micro-Bypass System Model iS3$3,088
- Hydrus$2,500
How this compares
$608,796 in reported general payments places this provider in the 95th percentile of 674 ophthalmology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 91 | $48,770 |
| VyzultaLatanoprostene Bunod | 92 | $46,027 |
| RestasisCyclosporine | 44 | $34,508 |
| RhopressaNetarsudil Mesylate | 58 | $32,808 |
| CombiganBrimonidine Tartrate/Timolol | 65 | $23,269 |
| Alphagan PBrimonidine Tartrate | 26 | $12,138 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 50 | $11,466 |
| RocklatanNetarsudil Mesylat/Latanoprost | 19 | $11,243 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 361 | $6,698 |
| Cosopt PfDorzolamide/Timolol/Pf | 19 | $6,564 |
| Prednisolone Acetate | 110 | $6,255 |
| Brinzolamide | 36 | $6,085 |
| Brimonidine Tartrate | 108 | $4,890 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 28 | $4,790 |
| Latanoprost | 492 | $4,402 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $335,764 | $118,685226 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $9,063 | $46,02792 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $600 | $44,05277 claims |
| AlconSimbrinza | $113,757 | $11,46650 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 674 ophthalmology providers in Michigan.
Other ophthalmology in Ann Arbor
- David ZacksAnn Arbor$177K
- Jason MillerAnn Arbor$104K
- Yannis PaulusAnn Arbor$85K
- Shilpa KodatiAnn Arbor$75K
- Amanda BicketAnn Arbor$34K
- Vinay AakaluAnn Arbor$16K
- Nita ValikodathAnn Arbor$16K
- Marguerite WeinertAnn Arbor$16K
- Abigail FahimAnn Arbor$14K
- Shahzad MianAnn Arbor$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.